Relative Standard DeviationAAMA Metals Data APPENDIX B  5  2 Page 1 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

Lab: 1Lab: 1 ALUMINUM, UG/ LALUMINUM, L 70 60 80 60 50 Lab: 3Lab: 3 ALUMINUM, UG/ LALUMINUM, L 50 60 40 40 30 40 30 20 20 Lab: 2Lab: 2 ALUMINUM, UG/ LALUMINUM, L 20 10 10 0 012 012 012 180 Lab: 4Lab: 4 ALUMINUM, UG/ LALUMINUM, L Lab: 5Lab: 5 ALUMINUM, UG/ LALUMINUM, L 35 160 30 140 15 25 120 20 100 10 1580 Lab: 6Lab: 6 ALUMINUM, UG/ LALUMINUM, L 60 10 5 40 5 0 1 2 0 1 2 0 1 2 140 200 Lab: 7Lab: 7 ALUMINUM, UG/ LALUMINUM, L 150 Lab: 8Lab: 8 ALUMINUM, UG/ LALUMINUM, L 120 Lab: 9Lab: 9 ALUMINUM, UG/ LALUMINUM, L 100 100 100 80 60 0 50 40 0 20 012 012 012 Log 10 of Spike Concentration Relative Standard DeviationAAMA Metals Data Page 2 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

3000 140 300 120 2500 250 100 2000 200 80 1500 150 60 1000 100 40 20 500 50 0 0 0 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 ( o) Lab: 2Lab: 2 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value ( o) Lab: 3Lab: 3 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value Lab: 1Lab: 1 ARSENIC, UG/ LARSENIC, L ( o) Lab: 4Lab: 4 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value 300 1000 250 250 800 200 200 600 150 150 400 100 100 200 50 50 0 0 0 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 6Lab: 6 ARSENIC, UG/ LARSENIC, L ( o) Lab: 5Lab: 5 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value 2500 300 300 ( o) Lab: 7Lab: 7 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value ( o) Lab: 8Lab: 8 ARSENIC, UG/ LARSENIC, L open circle: positive of negative RSD value 2000 200 1500 200 1000 100 100 500 000 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 9Lab: 9 ARSENIC, UG/ LARSENIC, L Tue May 7 16: 55: 00 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 3 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

1200 ( o) ( o)

Lab: 1Lab: 1 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 800 300 1000 250 600 800 200 Lab: 2Lab: 2 CADMIUM, UG/ LCADMIUM, L Lab: 3Lab: 3 CADMIUM, UG/ LCADMIUM, L 600 400 150 400 100 200 200 50 0 0 0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0 300 ( o) ( o) ( o)

Lab: 4Lab: 4 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 300 ( o) Lab: 5Lab: 5 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 150 200 200 100 100 100 50 000  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0 Lab: 6Lab: 6 CADMIUM, UG/ LCADMIUM, L 400 300 400 250 300 ( o) ( o)

Lab: 9Lab: 9 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 200 300 200 150 200 100 100 100 50 0 ( o) ( o)

Lab: 7Lab: 7 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 0 ( o) Lab: 8Lab: 8 CADMIUM, UG/ LCADMIUM, L open circle: positive of negative RSD value 0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0  1.0  0.5 0.0 0.5 1.0 1.5 2.0 Tue May 7 16: 55: 02 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 4 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

2501000 800 800 ( o) ( o)

Lab: 1Lab: 1 CHROMIUM, UG/ LCHROMIUM, L open circle: positive of negative RSD value 200 600 Lab: 3Lab: 3 CHROMIUM, UG/ LCHROMIUM, L 600 150 400 400 100 200 50 200 00 Lab: 2Lab: 2 CHROMIUM, UG/ LCHROMIUM, L 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 600 40 Lab: 5Lab: 5 CHROMIUM, UG/ LCHROMIUM, L 300 400 ( o) ( o)

Lab: 4Lab: 4 CHROMIUM, UG/ LCHROMIUM, L open circle: positive of negative RSD value 30 200 20 200 100 10 00  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 6Lab: 6 CHROMIUM, UG/ LCHROMIUM, L 1500 6000 Lab: 7Lab: 7 CHROMIUM, UG/ LCHROMIUM, L Lab: 8Lab: 8 CHROMIUM, UG/ LCHROMIUM, L 800 5000 600 1000 4000 3000 400 2000 500 200 1000 000 ( o) Lab: 9Lab: 9 CHROMIUM, UG/ LCHROMIUM, L open circle: positive of negative RSD value  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Tue May 7 16: 55: 04 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 5 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

300 Lab: 1Lab: 1 COPPER, UG/ LCOPPER, L 100 100 250 80 80200 Lab: 2Lab: 2 COPPER, UG/ LCOPPER, L Lab: 3Lab: 3 COPPER, UG/ LCOPPER, L 150 60 60 100 40 40 50 20 20 0 0 0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 250 80 Lab: 4Lab: 4 COPPER, UG/ LCOPPER, L 200 200 60 150 150 40 100 100 20 Lab: 5Lab: 5 COPPER, UG/ LCOPPER, L 50 50 00  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 Lab: 6Lab: 6 COPPER, UG/ LCOPPER, L 250 200 ( o) Lab: 8Lab: 8 COPPER, UG/ LCOPPER, L open circle: positive of negative RSD value 250 200 150 200 150 150 100 100 100 50 Lab: 7Lab: 7 COPPER, UG/ LCOPPER, L 50 50 000 Lab: 9Lab: 9 COPPER, UG/ LCOPPER, L  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 Tue May 7 16: 55: 06 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 6 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

200 1200 150 ( o) ( o)

Lab: 1Lab: 1 LEAD, UG/ LLEAD, L open circle: positive of negative RSD value 150 Lab: 2Lab: 2 LEAD, UG/ LLEAD, L 1000 800 100 100 600 400 50 50 200 00 Lab: 3Lab: 3 LEAD, UG/ LLEAD, L 012 012 012 2500 50 3000 2000 40 15002000 ( o) Lab: 4Lab: 4 LEAD, UG/ LLEAD, L open circle: positive of negative RSD value 30 1000 20 1000 500 10 0 Lab: 5Lab: 5 LEAD, UG/ LLEAD, L 0 012 012 012 ( o) Lab: 6Lab: 6 LEAD, UG/ LLEAD, L open circle: positive of negative RSD value ( o) ( o)

Lab: 7Lab: 7 LEAD, UG/ LLEAD, L open circle: positive of negative RSD value 300 Lab: 8Lab: 8 LEAD, UG/ LLEAD, L 600 1200 1000 250 500 800 200 400 600 150 300 400 100 200 200 50 100 0 0 0 0 1 2 0 1 2 0 1 2 ( o) Lab: 9Lab: 9 LEAD, UG/ LLEAD, L open circle: positive of negative RSD value Tue May 7 16: 55: 08 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 7 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

400 250 600 300 ( o) ( o) ( o)

Lab: 2Lab: 2 MANGANESE, UG/ LMANGANESE, L open circle: positive of negative RSD value 200 400 Lab: 1Lab: 1 MANGANESE, UG/ LMANGANESE, L 150 200 100 200 100 50 00 0  101  101  101 Lab: 3Lab: 3 MANGANESE, UG/ LMANGANESE, L 2501000 60 800 ( o)

Lab: 4Lab: 4 MANGANESE, UG/ LMANGANESE, L open circle: positive of negative RSD value Lab: 5Lab: 5 MANGANESE, UG/ LMANGANESE, L 200 Lab: 6Lab: 6 MANGANESE, UG/ LMANGANESE, L 600 40 150 400 100 20 200 50 000  101  101  101 300 800 ( o) Lab: 8Lab: 8 MANGANESE, UG/ LMANGANESE, L open circle: positive of negative RSD value 150 250 600 200 100 150 ( o) Lab: 7Lab: 7 MANGANESE, UG/ LMANGANESE, L open circle: positive of negative RSD value 400 100 50 200 50 00  101  101  101 Lab: 9Lab: 9 MANGANESE, UG/ LMANGANESE, L Tue May 7 16: 55: 10 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 8 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 245.1 Cold Vapor)

500 250300 400 200 200 300 Lab: 1Lab: 1 MERCURY, UG/

LMERCURY, L ( o) ( o)

Lab: 2Lab: 2 MERCURY, UG/

LMERCURY, L open circle: positive of negative RSD value 150 ( o) ( o)

Lab: 3Lab: 3 MERCURY, UG/

LMERCURY, L open circle: positive of negative RSD value 200 100 100 100 50 0  3  2  1 0  3  2  1 0  3  2  1 0 200 250 Lab: 4Lab: 4 MERCURY, UG/

LMERCURY, L Lab: 5Lab: 5 MERCURY, UG/

LMERCURY, L 140 150 200 120 150 100 100 100 50 50 80 Lab: 6Lab: 6 MERCURY, UG/

LMERCURY, L  3 2 1 0  3 2 1 0  3 2 1 0 Lab: 9Lab: 9 MERCURY, UG/

LMERCURY, L 5000 80 300 4000 250 60 200 3000 150 40 2000 100 1000 50 Lab: 7Lab: 7 MERCURY, UG/

LMERCURY, L ( o) ( o)

Lab: 8Lab: 8 MERCURY, UG/

LMERCURY, L open circle: positive of negative RSD value 20 00  3 2 1 0  3 2 1 0  3 2 1 0 Wed May 8 15: 03: 41 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 9 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

400 Lab: 1Lab: 1 MOLYBDENUM, UG/ LMOLYBDENUM, L 800 50 300 600 40 200 400 ( o)

Lab: 2Lab: 2 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 30 20 100 200 10 00 Lab: 3Lab: 3 MOLYBDENUM, UG/ LMOLYBDENUM, L  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 140 150 120 150 100 100 100 ( o) ( o)

Lab: 4Lab: 4 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value Lab: 5Lab: 5 MOLYBDENUM, UG/ LMOLYBDENUM, L 80 60 50 50 40 20 00  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 6Lab: 6 MOLYBDENUM, UG/ LMOLYBDENUM, L ( o) ( o)

Lab: 7Lab: 7 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 500 ( o) Lab: 8Lab: 8 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 300 25000 400 250 20000 200 300 15000 150 ( o) Lab: 9Lab: 9 MOLYBDENUM, UG/ LMOLYBDENUM, L open circle: positive of negative RSD value 10000 200 100 5000 100 50 0 0 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Tue May 7 16: 55: 14 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 10 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

400 ( o) ( o)

Lab: 1Lab: 1 NICKEL, UG/ LNICKEL, L open circle: positive of negative RSD value 1000 ( o) ( o)

Lab: 2Lab: 2 NICKEL, UG/ LNICKEL, L open circle: positive of negative RSD value 150 800 300 100 600 200 400 50 100 200 000  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 Lab: 3Lab: 3 NICKEL, UG/ LNICKEL, L 400 Lab: 4Lab: 4 NICKEL, UG/ LNICKEL, L Lab: 5Lab: 5 NICKEL, UG/ LNICKEL, L 160 150 300 140 100 200 120 50 100 100 80 00  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 Lab: 6Lab: 6 NICKEL, UG/ LNICKEL, L ( o) Lab: 9Lab: 9 NICKEL, UG/ LNICKEL, L open circle: positive of negative RSD value 200 200 2000 150 150 1500 100 100 1000 50 Lab: 7Lab: 7 NICKEL, UG/ LNICKEL, L 50 Lab: 8Lab: 8 NICKEL, UG/ LNICKEL, L 500 000  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0  0.5 0.0 0.5 1.0 1.5 2.0 Tue May 7 16: 55: 16 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Page 11 of 13 Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

300 ( o) Lab: 1Lab: 1 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value 8000 ( o) Lab: 2Lab: 2 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value 400 Lab: 3Lab: 3 SELENIUM, UG/ LSELENIUM, L 250 6000 300 200 150 4000 200 100 2000 100 50 000 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 1200 2000 ( o) ( o) ( o)

Lab: 4Lab: 4 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value 200 1000 1500 150 800 1000 100 Lab: 5Lab: 5 SELENIUM, UG/ LSELENIUM, L 600 400 500 50 200 00 0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Lab: 6Lab: 6 SELENIUM, UG/ LSELENIUM, L 200 ( o) Lab: 7Lab: 7 SELENIUM, UG/ LSELENIUM, L open circle: positive of negative RSD value Lab: 8Lab: 8 SELENIUM, UG/ LSELENIUM, L 800 500 150 400 600 300 100 400 200 50 200 100 000 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0 Lab: 9Lab: 9 SELENIUM, UG/ LSELENIUM, L Tue May 7 16: 55: 18 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES) 250 500 ( o)

Lab: 1Lab: 1 SILVER, UG/ LSILVER, L open circle: positive of negative RSD value 200 200400 150 300 ( o) ( o)

Lab: 2Lab: 2 SILVER, UG/ LSILVER, L open circle: positive of negative RSD value 150 Page 12 of 13 Lab: 3Lab: 3 SILVER, UG/ LSILVER, L 100 200 100 100 50 50 0 0 0  1012  1012  1012 250 200 Lab: 4Lab: 4 SILVER, UG/ LSILVER, L 200 200 150 Lab: 5Lab: 5 SILVER, UG/ LSILVER, L 150 150 100 Lab: 6Lab: 6 SILVER, UG/ LSILVER, L 100 100 50 50 50 0  1 0 1 2  1 0 1 2  1 0 1 2 250 600 200 800 400 Lab: 7Lab: 7 SILVER, UG/ LSILVER, L 150 600 100 400 200 50 Lab: 8Lab: 8 SILVER, UG/ LSILVER, L 200 00 0  1012  1012  1012 1000 Lab: 9Lab: 9 SILVER, UG/ LSILVER, L Tue May 7 16: 55: 20 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s Relative Standard DeviationAAMA Metals Data Relative Standard Deviation vs Spike Concentrations ( Log 10 Scale)

( Matrix A, Method EPA 200.7 ICP/ AES)

2500 60 Lab: 1Lab: 1 ZINC, UG/ LZINC, L ( o) ( o)

Lab: 2Lab: 2 ZINC, UG/ LZINC, L open circle: positive of negative RSD value 60 2000 40 1500 40 1000 20 20 500 000  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Page 13 of 13 Lab: 3Lab: 3 ZINC, UG/ LZINC, L 100 300 Lab: 4Lab: 4 ZINC, UG/ LZINC, L 80 Lab: 5Lab: 5 ZINC, UG/ LZINC, L 80 60 60 200 40 40 100 20 20 0  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 6Lab: 6 ZINC, UG/ LZINC, L 40 Lab: 7Lab: 7 ZINC, UG/ LZINC, L 120 Lab: 8Lab: 8 ZINC, UG/ LZINC, L 400 100 30 300 80 60 200 20 40 100 10 20 00  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5  0.5 0.0 0.5 1.0 1.5 2.0 2.5 Lab: 9Lab: 9 ZINC, UG/ LZINC, L Tue May 7 16: 55: 22 2002 Log 10 of Spike Concentration c:/ pw/ ostmdl/ req005/ r005sd2. s


[Federal Register: November 19, 2009 (Volume 74, Number 222)]
[Notices]
[Page 60018]
[DOCID:fr19no09-87]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Office of the Secretary

Aviation Proceedings, Agreements Filed the Week Ending October
31, 2009

    The following Agreements were filed with the Department of
Transportation under the Sections 412 and 414 of the Federal Aviation
Act, as amended (49 U.S.C. 1383 and 1384) and procedures governing
proceedings to enforce these provisions. Answers may be filed within 21
days after the filing of the application.

    Docket Number: DOT-OST-2009-0270.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Middle East-South East Asia Expedited, Resolution
002am and Specified Fares Tables (Memo 0422). Intended effective date:
1 January 2010.

    Docket Number: DOT-OST-2009-0271.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Middle East-Japan, Korea Expedited, Resolutions
and Specified Fares Tables (Memo 0424). Intended effective date: 1
December 2009.

    Docket Number: DOT-OST-2009-0272.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Africa-Japan, Korea Expedited Resolution 002aj
and Specified Fares Tables (Memo 0418). Intended effective date: 1
December 2009.

    Docket Number: DOT-OST-2009-0273.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Africa-South East Asia Expedited Resolution 002ao
(Memo 0421). Intended effective date: 1 December 2009.

    Docket Number: DOT-OST-2009-0274.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Africa-South East Asia Expedited, Resolution
002ap and Specified Fares Tables (Memo 0422). Intended effective date:
1 January 2010.

    Docket Number: DOT-OST-2009-0275.
    Date Filed: October 26, 2009.
    Parties: Members of the International Air Transport Association.
    Subject: TC23/123 Africa-Japan, Korea Expedited, Resolutions and
Specified Fares Tables (Memo 0419). Intended effective date: 15 January
2010.

Renee V. Wright,
Program Manager, Docket Operations, Federal Register Liaison.
[FR Doc. E9-27782 Filed 11-18-09; 8:45 am]

BILLING CODE 4910-9X-P


BIOPESTICIDES REGISTRATION ACTION DOCUMENT

Sarmentine

PC Code :	373501

	U.S. Environmental Protection Agency

	Office of Pesticide Programs

Biopesticides and Pollution Prevention Division

August 7, 2014

TABLE OF CONTENTS

  TOC \o "1-4" \h \z \u    HYPERLINK \l "_Toc394409661"  I.	EXECUTIVE
SUMMARY	  PAGEREF _Toc394409661 \h  5

  HYPERLINK \l "_Toc394409662"  II.	ACTIVE INGREDIENT OVERVIEW	  PAGEREF
_Toc394409662 \h  6

  HYPERLINK \l "_Toc394409663"  III.	REGULATORY BACKGROUND	  PAGEREF
_Toc394409663 \h  6

  HYPERLINK \l "_Toc394409664"  A.	Classification	  PAGEREF
_Toc394409664 \h  6

  HYPERLINK \l "_Toc394409665"  B.	Food Clearances/Tolerances	  PAGEREF
_Toc394409665 \h  6

  HYPERLINK \l "_Toc394409666"  IV.	RISK ASSESSMENT	  PAGEREF
_Toc394409666 \h  6

  HYPERLINK \l "_Toc394409667"  A.	Active Ingredient Characterization
PAGEREF _Toc394409667 \h  6

  HYPERLINK \l "_Toc394409668"  1.	Toxicology	  PAGEREF _Toc394409668 \h
 7

  HYPERLINK \l "_Toc394409669"  2.	Dose Response Assessment	  PAGEREF
_Toc394409669 \h  9

  HYPERLINK \l "_Toc394409670"  3.	Drinking Water Exposure and Risk
Characterization	  PAGEREF _Toc394409670 \h  9

  HYPERLINK \l "_Toc394409671"  4.	Occupational, Residential, School and
Day Care Exposure and Risk Characterization	  PAGEREF _Toc394409671 \h
9

  HYPERLINK \l "_Toc394409674"  5.      	Risk Characterization	  PAGEREF
_Toc394409674 \h  10

  HYPERLINK \l "_Toc394409675"  C.	ENVIRONMENTAL ASSESSMENT	  PAGEREF
_Toc394409675 \h  10

  HYPERLINK \l "_Toc394409676"  1.	Ecological Hazards	  PAGEREF
_Toc394409676 \h  10

  HYPERLINK \l "_Toc394409677"  2.	Environmental Fate and Ground Water
Data	  PAGEREF _Toc394409677 \h  10

  HYPERLINK \l "_Toc394409678"  3.	Ecological Exposure and Risk
Characterization	  PAGEREF _Toc394409678 \h  10

  HYPERLINK \l "_Toc394409679"  4.   	Endangered Species Assessment
PAGEREF _Toc394409679 \h  10

  HYPERLINK \l "_Toc394409680"  D.	PRODUCT PERFORMANCE DATA (EFFICACY)
PAGEREF _Toc394409680 \h  10

  HYPERLINK \l "_Toc394409681"  V.	Risk Management Decision	  PAGEREF
_Toc394409681 \h  11

  HYPERLINK \l "_Toc394409682"  A.	Determination of Eligibility for
Registration	  PAGEREF _Toc394409682 \h  11

  HYPERLINK \l "_Toc394409683"  B.	Regulatory Decision	  PAGEREF
_Toc394409683 \h  11

  HYPERLINK \l "_Toc394409684"  1.	Conditional/Unconditional
Registration	  PAGEREF _Toc394409684 \h  11

  HYPERLINK \l "_Toc394409685"  C. 	Environmental Justice	  PAGEREF
_Toc394409685 \h  11

  HYPERLINK \l "_Toc394409686"  VI.	ACTIONS REQUIRED BY REGISTRANTS
PAGEREF _Toc394409686 \h  12

  HYPERLINK \l "_Toc394409687"  A.  	Reporting of Adverse Effects
PAGEREF _Toc394409687 \h  12

  HYPERLINK \l "_Toc394409688"  B.	Reporting of Hypersensitivity
Incidents	  PAGEREF _Toc394409688 \h  12

  HYPERLINK \l "_Toc394409689"  VII.	Appendix A. Data Requirements (40
CFR Part 158-Subpart U)	  PAGEREF _Toc394409689 \h  12

  HYPERLINK \l "_Toc394409690"  VIII. 	Appendix B.	  PAGEREF
_Toc394409690 \h  15

  HYPERLINK \l "_Toc394409691"  IX.	Appendix C.	  PAGEREF _Toc394409691
\h  16

  HYPERLINK \l "_Toc394409692"  X.  	GLOSSARY OF ACRONYMS AND
ABBREVIATIONS	  PAGEREF _Toc394409692 \h  16

BIOPESTICIDES REGISTRATION ACTION DOCUMENT TEAM

Office of Pesticide Programs:

Biopesticides and Pollution Prevention Division

Biochemical Pesticides Branch (BPB)

Leonard S. Cole, Jr., M.S.						Senior Regulatory Specialist

EXECUTIVE SUMMARY

Sarmentine is a new biochemical active ingredient intended for use as an
herbicide to control grasses and broadleaf weeds in and around crops. It
is used as a foliar and spot treatment spray on non-food crops in
agricultural, residential, and other areas such as golf courses and
parks. It is a naturally occurring constituent of peppercorns that has
been extracted from fruit, foliage and roots of a variety of pepper
plants. Sarmentine has been characterized in alcohol extracts from a
variety of edible peppers, including Piper sarmentosum, Piper longnum,
and Piper nigrum, the source of both common black and white peppers.
Sarmentine has also been isolated from vines in the Vitus family, which
includes grapes. Although the specific mode of action of sarmentine is
not completely understood, it is believed that the substance damages and
degrades the integrity of plant cell walls. Based on this information,
the Agency considers the mode of action to be non-toxic.

The Biopesticides and Pollution Prevention Division (BPPD) has reviewed
all of the data and other information submitted in support of the
registration of sarmentine as an herbicide under section 3(c)(5) of the
Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), and has
determined that the current data requirements (40 CFR part 158.2010
through 158.2070) for registration of a biochemical pesticide have been
satisfied. Given that sarmentine is of low toxicity and presents little,
if any, risks to humans, including infants and children, and the
environment, the U.S. Environmental Protection Agency (EPA or the
Agency) has concluded that it is in the best interest of the public to
issue registrations for the manufacturing-use product (MP), MBI-011 TGAI
(EPA File Symbol No. 84059-RO), and the end-use product (EP), MBI-011 EP
(EPA File Symbol No. 84059-EN) which contain this new active ingredient,
sarmentine. The basis for this decision is described in more detail in
section IV of this Biopesticide Registration Action Document (BRAD).

On October 1, 2009, EPA announced a new policy to provide a more
meaningful opportunity for the public to participate on major
registration decisions before they occur. According to this policy, EPA
provides a public comment period prior to making a registration decision
for the following types of applications:  new active ingredients, first
food use, first outdoor use, first residential use, and any registration
decisions for which the Agency believes there may be substantial public
interest.

Consistent with the new policy of making registration actions more
transparent, sarmentine is subject to a 15 day comment period as a
“new active ingredient”. EPA has established a comment period of 15
days on the basis of sarmentine’s low toxicity, the determination that
sarmentine presents low risk of any adverse effects to human health and
the environment, and a need for this active ingredient. The notice for
this comment period includes the draft Biopesticides Registration Action
Document (BRAD), and a draft product label for the MP, MBI-011 and EP,
MBI-011, which contain this new active ingredient, sarmentine. The
docket ID is EPA-HQ-OPP-2014-0003. The Agency believes that based on the
risk assessment and information submitted in support of the registration
of sarmentine, it is in the best interests of the public to issue the
registration of MBI-011 TGAI and MBI-011 EP. The basis for this decision
can be found in the risk assessment for sarmentine, which is
characterized in this BRAD.

II.		ACTIVE INGREDIENT OVERVIEW

Common Name: 			Sarmentine

Chemical Names: 	(E,E)-1-(1-oxo-2,4-decadienyl) pyrrolidine

Trade & Other Names: 	MBI-011

CAS Registry Number: 	78910-33-5

OPP Chemical Code: 	373501

Type of Pesticide: 		Herbicide

III.	REGULATORY BACKGROUND

On December 31, 2012, EPA received an application filed by Marrone Bio
Innovations, 2121 Second Street, Suite B107, Davis, California 95618 to
register the products, MBI-011 TGAI (EPA File Symbol 84059-RO) and
MBI-011 EP (EPA File Symbol 84059-EN), containing the new biochemical
active ingredient (E,E)-1-(1-oxo-2,4-decadienyl) pyrrolidine known as
sarmentine. A notice of receipt of this application, allowing for a
30-day comment period, was published in the Federal Register of April
18, 2014 (79 FR 75). No comments were received following this
publication.

A.	Classification

On October 14, 2010, the Biochemical Classification Committee determined
that sarmentine can be classified as a biochemical pesticide due to its
non-toxic mode of action, natural occurrence in the environment, and
history of exposure to humans and the environment demonstrating minimal
toxicity.

B.	Food Clearances/Tolerances

Currently, sarmentine is not intended for use on food or feed
commodities; therefore, a tolerance or exemption from the requirement of
a tolerance is not relevant. Sarmentine has been determined to be a
non-food use.

IV.			RISK ASSESSMENT

Active Ingredient Characterization

The new active ingredient sarmentine (MP, MBI-011) will be formulated as
an EP to be used as an herbicide on non-food use sites. Sarmentine is a
naturally-occurring biochemical isolated from pepper fruit, foliage and
roots. Sarmentine is naturally occurring and is found in many plants
within the Piper family, which is the source of the spice “pepper”.
Sarmentine has also been isolated from vines in the Vitus family, which
includes grapes. Sarmentine has been characterized in alcohol extracts
from a variety of edible peppers, including Piper sarmentosum, Piper
longnum, and Piper nigrum, the source of both common black and white
peppers.

Descriptions of the product formulation and production process, as well
as the formation of impurities, were examined by BPPD and found to be
acceptable in meeting current guideline standards.

All product chemistry data requirements for registration of sarmentine
have been satisfied.

B.	Human Health Assessment

1.	Toxicology

For acute toxicity data requirements, toxicity categories are assigned
based on the hazard(s) identified from studies and/or information on
file with the Agency.  The active ingredient is classified into acute
Toxicity Category I, II, III or IV where Toxicity Category I is the
level of highest toxicity and Toxicity Category IV indicates low
toxicity.

Adequate mammalian toxicology data/information are available to support
registration of sarmentine. All toxicology data requirements for
sarmentine have been satisfied.

	a.	Acute Toxicity

Acute toxicity testing is required to 1) determine systemic toxicity
from acute exposure via the dermal, inhalation and oral routes, 2)
determine irritant effects from exposure to the eyes, and 3) determine
the potential for skin sensitization (allergic contact dermatitis).

Tier I acute toxicity studies submitted and reviewed showed that
sarmentine is a Toxicity Category II (moderately irritating) compound
via primary eye irritation exposure. Sarmentine is a Toxicity Category
IV for acute inhalation, primary dermal irritation, and acute oral
toxicity routes of exposure. Submitted information confirmed that
sarmentine is a dermal sensitizer.

For more information regarding acute toxicity data requirements, refer
to Table 3 in Appendix A of this document.

	b.	Subchronic Toxicity

Subchronic data are required to determine a no-observed-effect-level
(NOEL) and toxic effects (if any) associated with repeated or continuous
exposure to a test substance for a period of 90 days.

Data waivers requested for the subchronic [90-day oral (OSCPP 870.3100),
90-day dermal (OSCPP 870.3250), and 90-day inhalation (OSCPP 870.3465)]
studies were granted by BPPD, based on the product’s toxicological and
exposure profile below.

Sarmentine is for non-food use; therefore, repeat oral exposure to
humans is not anticipated.

Prolonged exposure to human skin is not anticipated based on the use
pattern and the use of personal protective equipment is required in
occupational settings.

Significant inhalation exposure is not expected based on the use
pattern.

For more information regarding the subchronic data requirements, refer
to Table 3 in Appendix A of this document.

      	c.   	Developmental Toxicity and Mutagenicity

Data waivers were granted for Tier I Subchronic, Developmental and
Mutagenicity data requirements (OSCPP 870.3100 to 870.5375) due to the
nature of the A.I. and its intended uses. Significant exposure to humans
is unlikely based on the proposed use pattern of the active ingredient.
Exposure via the oral route is not anticipated as sarmentine is intended
for non-food uses. Further, applicators and handlers must wear PPE to
preclude significant dermal and inhalation exposure. Significant
residential exposures are also not anticipated because any exposures
would be acute in nature and not prolonged. Further, exposure will be
mitigated because sarmentine is expected to degrade rapidly into
innocuous substances once applied; thus, significant post-application
exposure is not likely.

d. 	Tier II/Tier III

Tiers II and III data were not triggered due to low toxicity profile of
sarmentine and low exposure to humans and non-target species.

	e.	Effects on the Endocrine System tc \l4 "e.	Effects on the Endocrine
System

As required under Federal Food, Drug, and Cosmetic Act (FFDCA) section
408(p), EPA has developed the Endocrine Disruptor Screening Program
(EDSP) to determine whether certain substances  (including pesticide
active and other ingredients) may have an effect in humans or wildlife
similar to an effect produced by a “naturally-occurring estrogen, or
other such endocrine effects as the Administrator may designate.” The
EDSP employs a two-tiered approach to making the statutorily required
determinations. Tier I consists of a battery of 11 screening assays to
identify the potential of a chemical substance to interact with the
estrogen, androgen, or thyroid (E, A, or T) hormonal systems. Chemicals
that go through Tier I screening and are found to have the potential to
interact with E, A, or T hormonal systems will proceed to the next stage
of the EDSP where EPA will determine which, if any, of the Tier 2 tests
are necessary based on the available data. Tier 2 testing is designed to
identify any adverse endocrine related effects caused by the substance,
and establish a dose-response relationship between the dose and the E,
A, or T effect.

Between October 2009 and February 2010, EPA issued test orders/data
call-ins for the first group of 67 chemicals, which contains 58
pesticide active ingredients and nine inert ingredients. This list of
chemicals was selected based on the potential for human exposure through
pathways such as food and water, residential activity, and certain
post-application agricultural scenarios. This list should not be
construed as a list of known or likely endocrine disruptors.

Sarmentine is not among the group of 58 pesticide active ingredients on
the initial list to be screened under the EDSP. Under FFDCA section
408(p) the Agency must screen all pesticide chemicals. Accordingly, EPA
anticipates issuing future test orders/data call-ins for all pesticide
active ingredients.

For further information on the status of the EDSP, the policies and
procedures, the list of 67 chemicals, the test guidelines and the Tier I
screening battery, please visit our website:  http://www.epa.gov/endo/.

2.	Dose Response Assessment

There are no available repeat dose studies; therefore, a dose response
cannot be established.

3.	Drinking Water Exposure and Risk Characterization

No significant exposure via drinking water is expected when sarmentine
is used according to the product label directions. Sarmentine is not to
be applied directly to water or to areas where surface water is present,
and if used as labeled, is not likely to accumulate in drinking water.
Sarmentine is expected to degrade rapidly in the environment once
applied, based on the half-life of 30-45 minutes. In the unlikely event
that exposure via drinking water did occur, the health risk would be
expected to be minimal based on the rapid degradation of sarmentine.

4.	Occupational, Residential, School and Day Care Exposure and Risk
Characterization

	a.	Occupational Exposure and Risk Characterization

An occupational exposure assessment was not conducted for sarmentine.
Based on the proposed use pattern and toxicity data available to the
Agency, expected exposure is not likely to result in unreasonable risk
to applicators/handlers. Occupational exposure is not anticipated
because applicators and handlers are required to wear PPE that would
mitigate exposure to the active ingredient. Additionally, sarmentine is
expected to degrade rapidly into innocuous substances once applied,
which would greatly reduce the potential for post-application exposure.
In the event that exposure does occur, adverse effects are not expected
due to the low toxicity of the A.I.

b.	Residential, School and Day Care Exposure and Risk Characterization

Based on the proposed use pattern and toxicity data available to the
Agency, residential exposure is not likely to result in unreasonable
risk to humans. Although significant exposures are not anticipated, any
exposures that might occur would be incidental, acute in nature, and not
prolonged because of the way in which the proposed product is intended
for use. That is, as a spot treatment to weeds applied via a tank
sprayer as a course spray. Further, exposure will also be reduced
because sarmentine is expected to degrade rapidly into innocuous
substances once applied. Thus, post application exposure is not likely.
No relevant toxicological endpoints were identified and therefore,
exposure should it occur, will be appropriately mitigated for the
reasons stated above in addition and when proper label instructions are
followed.

5.   Risk Characterization

The Agency considered human exposure to sarmentine after reviewing the
available toxicity data. A determination has been made that no
unreasonable exposure to the U.S. population in general, and to infants
and children in particular, will result from the use of sarmentine when
label instructions are followed.

C.	ENVIRONMENTAL ASSESSMENT

1.	Ecological Hazards

Adequate non-target toxicology data/information are available to support
the registration of the biochemical pesticide, sarmentine. All
non-target toxicology data requirements for sarmentine have been
satisfied. Non-Target Organisms and Environmental Fate data requirements
were waived or satisfied by data/information submitted by the applicant.

2.	Environmental Fate and Ground Water Data

The need for environmental fate and groundwater data was not triggered
because results of the acute toxicity studies did not trigger any
additional Tier II studies. Further, sarmentine degrades rapidly into
innocuous substances in the environment once applied.

3.	Ecological Exposure and Risk Characterization

Data waivers were granted for non-target plants and non-target insect
testing based on data/information which demonstrate that sarmentine is
non-toxic to ladybugs when applied to the beetle’s food source and
corn earworn eggs. Appropriate mitigation language on the EP label will
prevent exposure to desirable or non-target plants. In addition, avian
dietary exposure is not anticipated based on the use pattern and rapid
degradation in the environment.

4.   Endangered Species Assessment

Sarmentine is not toxic to non-target organisms, and based on its use
pattern EPA has determined it will have No Effect on threatened and/or
endangered species or any designated critical habitat.

D.	PRODUCT PERFORMANCE DATA (EFFICACY)

Product Performance data must be developed for all pesticides to ensure
that pesticide products will perform as intended and that unnecessary
pesticide exposure to the environment will not occur as a result of the
use of ineffective products. The Agency reserves the right to require on
a case-by-case basis, submission of efficacy data for any pesticide
product registered or proposed for registration that are intended to be
used to control a pest of significancant public health importance and a
public health pest as defined in FIFRA section 28(d) and section 2(nn).
For further guidance on product performance requirement, refer to
Pesticide Registration Notice (PR) Notices 96-7, 2002-1 and Explanation
of Statutory Framework for Risk-Benefit Balancing for Public Health
Pesticides (  HYPERLINK "http://www.epa.gov/PR_Notices/pr1996-7.pdf"
http://www.epa.gov/PR_Notices/pr1996-7.pdf ) (  HYPERLINK
"http://www.epa.gov/PR_Notices/pr2002-1.pdf"
http://www.epa.gov/PR_Notices/pr2002-1.pdf ) and (  HYPERLINK
"http://www.epa.gov/pesticides/health/risk-benefit.htm"
http://www.epa.gov/pesticides/health/risk-benefit.htm .

The EP submitted with this new active ingredient did not list pests of
significant public health importance or a public health pest as defined
in FIFRA section 28(d) and section 2(nn). Therefore, product performance
(efficacy) was not evaluated.

V.		Risk Management Decision

A.	Determination of Eligibility for Registration

Section 3(c)(5) of FIFRA provides for the registration of new active
ingredients if it is determined that: (A) its composition warrants
proposed claims; (B) its labeling and other materials comply with the
requirements of FIFRA; (C) it will perform its intended function without
unreasonable adverse effects on the environment; and (D) when used in
accordance with widespread and commonly recognized practice, it will not
generally cause unreasonable adverse effects on the environment.

The four criteria of the Eligibility Determination for Pesticidal Active
Ingredients are satisfied by the science assessments supporting products
containing sarmentine. Such products are not expected to cause
unreasonable adverse effects and are likely to provide protection as
claimed when used according to label instructions. Therefore, sarmentine
is eligible for registration for the labeled uses.

B.	Regulatory Decision

The data submitted fulfill the requirements of registration for
sarmentine for use as an herbicide. Refer to Appendix B for
product-specific information.

1.	Conditional/Unconditional Registration

All data requirements are fulfilled and EPA has determined that
unconditional registration of sarmentine is appropriate.

C. 	Environmental Justice

EPA seeks to achieve environmental justice--the fair treatment and
meaningful involvement of all people regardless of race, color, national
origin, or income--with respect to the development, implementation, and
enforcement of environmental laws, regulations, and policies. At this
time, EPA does not believe that use of sarmentine pesticide products
will cause harm of a disproportionate impact on at-risk communities. For
additional information regarding environmental justice issues, please
visit EPA’s website at   HYPERLINK
"http://www.epa.gov/compliance/environmentaljustice/index.html"
http://www.epa.gov/compliance/environmentaljustice/index.html .

VI.	 	ACTIONS REQUIRED BY REGISTRANTS

EPA evaluated all of the data submitted in connection with the initial
registration of sarmentine and determined that these data are sufficient
to satisfy current registration data requirements.  No additional data
are required to be submitted to the Agency at this time.  For new uses
and/or changes to existing uses, additional data may be required.

Not withstanding, the information stated in the previous paragraph, it
should be clearly understood that certain, specific, data are required
to be reported to the Agency as a requirement for maintaining the
Federal registration for a pesticide product. A brief summary of these
types of data are listed below.

A.  Reporting of Adverse Effects

Additionally, all incidents of hypersensitivity (including both
suspected and confirmed incidents) must be reported to the Agency under
the provisions of 40 CFR § 158.2050(d).

B.	Reporting of Hypersensitivity Incidents

Additionally, all incidents of hypersensitivity (including both
suspected and confirmed incidents) must be reported to the Agency under
the provisions of 40 CFR Part 158.2050(d).

VII.	Appendix A. Data Requirements (40 CFR Part 158-Subpart U)

*NOTE:  MRID numbers listed in the following tables are representative
of supporting data for the original registration of the product
containing this active ingredient.  Subsequent to this registration,
there may be additional MRIDs that support registration of other
products containing this active ingredient.

TABLE 1. Product Chemistry Data Requirements for Sarmentine (40 CFR §
158.2030)

OPPTS Guideline No.	Study	Results

830.1550

to

830.1670	Product identity;

Manufacturing process;

Discussion of formation of unintentional ingredients	Submitted data
satisfy the requirements for product identity, manufacturing process,
and discussion of formation of impurities.

830.1700	Analysis of samples	Submitted data satisfy the requirements for
analysis of samples.

830.1750	Certification of limits	Limits listed in the CSF are
acceptable.

830.1800	Analytical method	Acceptable.

	TABLE 2. Physical and Chemical Properties of Sarmentine (MBI-011 TGAI)
(40 CFR § 158.2030)

OCSPP Guideline 	Property	Description of Result	MRID

830.6302	Color	Light yellow	49020301

830.6303	Physical State	Solid (powder)	49020301

830.6304	Odor	None detected	49020301

830.6313	Stability to Normal and Elevated Temperatures, Metals and Metal
Ions	Not expected to be stable at temperatures between 25°C and 40°C.
The active ingredient is not anticipated to come in contact with metals
or metal ions during storage.	49020303

830.6315	Flammability	N/A: product does not contain combustible liquids.
49020303

830.6317	Storage Stability	A storage stability study is ongoing.
49020303

830.6319	Miscibility	N/A: product is not an emulsifiable liquid to be
diluted with petroleum solvents.	49020303

830.6320	Corrosion Characteristics	A corrosion characteristics study is
ongoing. 	49020303

830.7000	pH	4.34	49020301

830.7050	UV/Visible Light

Absorption	ɛ= 3071 (neutral), 3090 (acidic), 3127 (basic)	49020301

830.7100	Viscosity	N/A: test substance is a solid.	49020301

830.7200	Melting Point/Range	Method needed

	830.7220	Boiling Point/Range	>400°C	49020301

830.7300	Bulk Density	1.28 g/ml	49020301

830.7520	Particle Size, Fiber Length and Diameter Distribution	5.707µm
Unassigned MRID

830.7550

830.7560

830.7570	Partition Coefficient (n-

Octanol/Water)

Not required: test substance is partially soluble in water.

49020303

830.7840	Water Solubility	1.57 g/100ml	49020302

830.7950	Vapor Pressure	Test substance is too unstable for testing.
49020302

Table 3. Mammalian Toxicology Data for Sarmentine  (40 CFR § 158.2050)

Study/OCSPP Guideline No.	Results	Toxicity Category/Description	MRID

Acute oral toxicity (rat)

(870.1100)	LD50 > 5000 mg/kg (females)	IV	49020306

Acute dermal toxicity (rat)

(870.1200)	LD50 > 5050 mg/kg (females and males)	IV	49020307

Acute inhalation toxicity	 (rat)

(870.1300)	LC50 > 2.22 mg/l (females and males)	IV	49020308

Primary eye irritation (rabbit)

(870.2400)	Moderately irritating	II	49020309

Primary dermal irritation (rabbit)

(870.2500)	Slightly irritating	IV	49020310

Dermal sensitization (guinea pig)

(870.2600)	Is a sensitizer	N/A	49020311

90-Day oral toxicity

(870.3100)	Waived. Sarmentine is for non-food uses only. Uses are not
anticipated to result in repeat oral exposure to humans.

49020319

49131901

49207902

90-Day dermal toxicity

(870.3250)	Waived. Purposeful application and prolonged exposure to the
human skin is not anticipated based on the use pattern. Applicators and
handlers are required to wear appropriate PPE. Residential exposures
would be incidental and short in duration; thus, repeated exposure is
not anticipated. Additionally, sarmentine degrades rapidly into
innocuous substances in the environment once applied which further
mitigates exposure.

49020319

49131901

49207902

90-Day inhalation toxicity

(870.3465)	Waived. Significant repeat inhalation exposure to the active
ingredient as a gas, vapor or aerosol is unlikely. Applicators and
handlers are required to wear appropriate PPE. Residential exposures
would be incidental and short in duration; thus, repeated exposure is
not anticipated. Additionally, sarmentine degrades rapidly into
innocuous substances in the environment once applied which further
mitigates exposure.

49020319

49131901

49207902

Mutagenicity-in vitro studies

(870.5100)	Waived. Significant human exposure is unlikely based on use
pattern. Sarmentine is for nonfood-uses only. Applicators and handlers
are required to wear appropriate PPE. Residential exposures would be
incidental and short in duration; thus, repeated exposure is not
anticipated. Additionally, sarmentine degrades rapidly into innocuous
substances in the environment once applied which further mitigates
exposure.

49020319

49131901

49207902

Mutagenicity-in vivo micronucleus assay

(870.5395)	Waived. Significant human exposure is unlikely based on use
pattern. Sarmentine is for nonfood-uses only. Applicators and handlers
are required to wear appropriate PPE. Residential exposures would be
incidental and short in duration; thus, repeated exposure is not
anticipated. Additionally, sarmentine degrades rapidly into innocuous
substances in the environment once applied which further mitigates
exposure.

49020319

49131901

49207902

Developmental toxicity

(870.3700)	Waived. Significant exposure to females is unlikely based on
use pattern. Sarmentine is for non-food uses only. Applicators and
handlers are required to wear appropriate PPE. Residential exposures
would be incidental and short in duration; thus, repeated exposure is
not anticipated. Additionally, sarmentine degrades rapidly into
innocuous substances in the environment once applied which further
mitigates exposure.

49020319

49131901

49207902

TABLE 4.  Nontarget Organism Toxicity Requirements for Sarmentine
(MBI-011 TGAI) (40 CFR § 158.2060)

Study/OCSPP Guideline No.

/MRID No.	Results	Toxicity Category/Description	MRID

Avian acute oral toxicity

Colinus virginianus

(850.2100)	LD50 > 2,000 mg/kg	Practically non-toxic	49020314

Avian dietary toxicity

Colinus virginianus and Anas platyrhynchos

(850.2200)	Waived. Avian dietary exposure is not anticipated based on
the use pattern. The proposed EP containing sarmentine is applied as a
foliar spray to weeds and is not in a granular form that could be
attractive to birds. Sarmentine is expected to degrade rapidly into
innocuous substances in the environment once applied which would further
mitigate dietary exposure to birds. 	N/A	49020319

49207902

Freshwater fish LC50

(Oncorhynchus mykiss)

(850.1075)	LC50 = 9.38 mg/l	Moderately toxic	49020313

Aquatic invertebrate acute toxicity

(Daphnia magna)

(850.1010)

EL50 = 3.83 mg/l

Moderately toxic

49020312

Non-target plant studies-seedling emergence

(850.4100)	Waived. Sarmentine is a non-selective herbicide that will be
applied to weeds. The proposed EP label will include language to prevent
or mitigate exposure to desirable or nontarget plants. Exposure to
non-target plants will be further mitigated because sarmentine is
expected to degrade rapidly into innocuous substances in the
environment. 	N/A	49020319

49131901

Non-target plant studies-vegetative vigor

(850.4150)	Waived. Sarmentine is a non-selective herbicide that will be
applied to weeds. The proposed EP label will include language to prevent
or mitigate exposure to desirable or non-target plants. Exposure to
non-target plants will be further mitigated because sarmentine is
expected to degrade rapidly into innocuous substances in the
environment.	N/A	49020319

49131901

Nontarget insect testing (Apis mellifera)

(880.4350)	Honey bee: LD50 > 100 µg a.i./bee

Ladybird beetle: practically non-toxic when sarmentine was applied to
the beetle’s food source, corn earworm eggs.

Green lacewing:  practically non-toxic when sarmentine was applied to
the lacewing’s food source, corn earworm eggs.

	Practically non-toxic	49020315

49020316

49020317

VIII. 	Appendix B.

For product specific information, please refer to   HYPERLINK
"http://www.epa.gov/pesticides/pestlabels"
http://www.epa.gov/pesticides/pestlabels .

IX.			Appendix C.

REFERENCES

Bernabeu, M., Chinchilla, R. and Najera, C. 1995.
(2E,4E)-5-Tosyl-2,4-pentadienamides: New Dienic Sulfones for the
Stereoselective Synthesis of (2E,4E)-Dienamides, Tetrahedron Letter. 36:
3901-3904

Débieux J-L, & Bochet, CG, 2010. Photoinduced acyl transfer. J.
Physical Organic Chem. 10:1002/poc.1639.

HSDB, 2014. Succinic Acid. National Library of Medicine. Hazardous
Substances Data Bank (HSDB). May 23,	2014. <
http://toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp/~3QhRRm:1>

Kiuchi, F., Nakamura, N., Tsuda, Y., Kondo, K and Yoshimura, H. 1988.
Studies on Crude Drugs Effective on Visceral Larva Migrans. IV.
Isolation and Identification of Larvicidal Principles in Pepper Chemical
and Pharmaceutical Bulletin 36: 2452.

Likhitwitayawuid, K., Ruangrungsi, N, Lange, G and Decicco, C.. 1987.
Structural Elucidation and Synthesis of New Components isolated from
Piper Samentosum Tetrahedron 43: 3689-3694.

Trigui M, Pulvin S, Poupin P, Thomas D. 2003. Biodegradation of cyclic
amines by a Pseudomonas strain involves an amine mono-oxygenase. Can J.
Microbiol 49: 181-188.

WHO, 2006. Food Additive Series 56: Aliphatic and Aromatic Amines and
Amides. FAO/WHO Joint Expert Committee on Food Additives.
http://www.inchem.org/documents/jecfa/jecmono/v56je13.pdf

X.  		GLOSSARY OF ACRONYMS AND ABBREVIATIONS

BRAD	Biopesticides Registration Action Document

C.F.R.	Code of Federal Regulations

cSt	centistokes

EDSP	Endocrine Disruptor Screening Program

EP	end-use pesticide product

EPA	United States Environmental Protection Agency (the “Agency”)

FFDCA	Federal Food, Drug, and Cosmetic Act

FIFRA	Federal Insecticide, Fungicide, and Rodenticide Act

FR	Federal Register

g/cm3	grams per cubic centimeter

lb/gal	pounds per gallon

LD50	median lethal dose. A statistically derived single dose that can be
expected

	to cause death in 50% of the test animals when administered by the
route

	indicated (oral, dermal, or inhalation). It is expressed as a weight of

	substance per unit weight of animal (e.g., mg/kg).

mg/kg	milligrams per kilogram

mL	milliliter

MP	manufacturing-use pesticide product

MPCA 	microbial pest control agent

MRID No.	Master Record Identification Number

NIOSH 	National Institute for Occupational Safety and Health

OPP	Office of Pesticide Programs

PC Code	Pesticide Chemical Code

PPE	personal protective equipment

TGAI 	technical grade of the active ingredient

U.S. 		   United States

Biopesticides Registration Action Document

Sarmentine

 PAGE

  PAGE   \* MERGEFORMAT  6


[Federal Register Volume 80, Number 193 (Tuesday, October 6, 2015)]
[Rules and Regulations]
[Page 60294]
[FR Doc No: 2015-25367]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 117

[Docket No. USCG-2015-0933]

Drawbridge Operation Regulations; Trent River, New Bern, NC

AGENCY: Coast Guard, DHS.

ACTION: Notice of deviation from drawbridge regulations.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard has issued a temporary deviation from the
operating schedule that governs the U.S. 70 (Alfred C. Cunningham)
Bridge across the Trent River, mile 0.0, at New Bern, NC. This
deviation allows the bridge to remain in the closed-to-navigation
position to accommodate the free movement of pedestrians and vehicles
during the 2015 Neuse River Bridge Run.

DATES: This deviation is effective from 6:30 a.m. to 9:30 a.m. on
October 17, 2015.

ADDRESSES: The docket for this deviation, [USCG-2015-0933], is
available at http://www.regulations.gov. Type the docket number in the
``SEARCH'' box and click ``SEARCH''. Click on Open Docket Folder on the
line associated with this deviation.

FOR FURTHER INFORMATION CONTACT: If you have questions on this
temporary deviation, call or email Mr. Hal R. Pitts, Bridge
Administration Branch Fifth District, Coast Guard; telephone (757) 398-
6222, email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The Event Director for the 2015 Neuse River
Bridge Run, with approval from the North Carolina Department of
Transportation, who owns and operates the U.S. 70 (Alfred C.
Cunningham) Bridge, has requested a temporary deviation from the
current operating regulations to accommodate the free movement of
pedestrians and vehicles during the 2015 Neuse River Bridge Run. The
bridge is a bascule bridge and has a vertical clearance in the closed
position of 14 feet above mean high water.
    The current operating schedule is set out in 33 CFR 117.843(a).
Under this temporary deviation, the bridge will be maintained in the
closed-to-navigation position from 6:30 a.m. to 9:30 a.m. on October
17, 2015. The Trent River is used by a variety of vessels including
small commercial vessels and recreational vessels. The Coast Guard has
carefully coordinated the restrictions with commercial and recreational
waterway users.
    Vessels able to pass through the bridge in the closed position may
do so at anytime. The bridge will be able to open for emergencies and
there is no alternate route for vessels unable to pass through the
bridge in the closed position. The Coast Guard will also inform the
users of the waterways through our Local and Broadcast Notice to
Mariners of the change in operating schedule for the bridge so that
vessels can arrange their transits to minimize any impacts caused by
this temporary deviation.
    In accordance with 33 CFR 117.35(e), the drawbridge must return to
its regular operating schedule immediately at the end of the effective
period of this temporary deviation. This deviation from the operating
regulations is authorized under 33 CFR 117.35.

    Dated: October 1, 2015.
Hal R. Pitts,
Bridge Program Manager, Fifth Coast Guard District.
[FR Doc. 2015-25367 Filed 10-5-15; 8:45 am]
 BILLING CODE 9110-04-P


[Federal Register Volume 77, Number 218 (Friday, November 9, 2012)]
[Notices]
[Pages 67352-67353]
[FR Doc No: 2012-27410]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 13739-002]

Lock+ Hydro Friends Fund XLII, LLC; Notice of Application
Accepted for Filing and Soliciting Motions To Intervene and Protests

    Take notice that the following hydroelectric application has been
filed

with the Commission and is available for public inspection.
    a. Type of Application: Major Original License
    b. Project No.: 13739-002
    c. Date filed: September 17, 2012
    d. Applicant: Lock+ Hydro Friends Fund XLII, LLC
    e. Name of Project: Braddock Locks and Dam Hydroelectric Project
    f. Location: At the existing U.S. Army Corps of Engineers' Braddock
Locks and Dam on the Monongahela River, in Allegheny County,
Pennsylvania. The project would occupy about 0.19 acre of federal
lands.
    g. Filed Pursuant to: Federal Power Act 16 USC 791(a)-825(r).
    h. Applicant Contact: Mr. Mark R. Stover, Lock+\TM\ Hydro Friends
Fund XLII, LLC, c/o Hydro Green Energy, LLC, 900 Oakmont Lane, Suite
310, Westmont, IL 60559;<PHONE_NUMBER> ext. 711; email_
<EMAIL_ADDRESS>    i. FERC Contact: John Mudre at<PHONE_NUMBER>; or email at
<EMAIL_ADDRESS>    j. Deadline for filing motions to intervene and protests: 60 days
from the issuance date of this notice.
    All documents may be filed electronically via the Internet. See 18
CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web
site http://www.ferc.gov/docs-filing/efiling.asp. Commenters can submit
brief comments up to 6,000 characters, without prior registration,
using the eComment system at http://www.ferc.gov/docs-filing/ecomment.asp. You must include your name and contact information at the
end of your comments. For assistance, please contact FERC Online
Support at<EMAIL_ADDRESS>or toll free at 1-866-208-3676,
or for TTY,<PHONE_NUMBER>. Although the Commission strongly encourages
electronic filing, documents may also be paper-filed. To paper-file,
mail an original and seven copies to: Kimberly D. Bose, Secretary,
Federal Energy Regulatory Commission, 888 First Street NE., Washington,
DC 20426.
    The Commission's Rules of Practice and Procedures require all
intervenors filing documents with the Commission to serve a copy of
that document on each person on the official service list for the
project. Further, if an intervenor files comments or documents with the
Commission relating to the merits of an issue that may affect the
responsibilities of a particular resource agency, they must also serve
a copy of the document on that resource agency.
    k. This application has been accepted for filing, but is not ready
for environmental analysis at this time.
    l. The proposed project would utilize the existing U.S. Army Corps
of Engineers' Braddock Locks and Dam and the Braddock Pool, and would
consist of the following new facilities: (1) A new powerhouse with five
turbine-generators having a total installed capacity of 3,750
kilowatts; (2) a new approximately 3,450-foot-long, 23-kilovolt
electric distribution line; (3) a switchyard and control room; and (4)
appurtenant facilities. The average annual generation is estimated to
be 25,020 megawatt-hours.
    The proposed project would deploy hydropower turbines within a
patented ``Large Frame Module'' (LFM) that would be deployed on the
south (river left) side of the dam, opposite the location of the
existing navigational locks and at the upstream face of the existing
left closure weir. The proposed modular, low environmental impact
powerhouse would be approximately 60.4 feet long, 16.6 feet wide, and
40 feet high, and constructed of structural-grade steel. The powerhouse
will bear on a concrete foundation on rock that is anchored to the
existing left closure weir. A trash rack with 6-inch openings would be
placed at the powerhouse intake to increase safety and protect the
turbines from large debris.
    m. A copy of the application is available for review at the
Commission in the Public Reference Room or may be viewed on the
Commission's Web site at http://www.ferc.gov using the ``eLibrary''
link. Enter the docket number excluding the last three digits in the
docket number field to access the document. For assistance, contact
FERC Online Support. A copy is also available for inspection and
reproduction at the address in item h above.
    You may also register online at http://www.ferc.gov/docs-filing/esubscription.asp to be notified via email of new filings and issuances
related to this or other pending projects. For assistance, contact FERC
Online Support.
    n. Any qualified applicant desiring to file a competing application
must submit to the Commission, on or before the specified intervention
deadline date, a competing development application, or a notice of
intent to file such an application. Submission of a timely notice of
intent allows an interested person to file the competing development
application no later than 120 days after the specified intervention
deadline date. Applications for preliminary permits will not be
accepted in response to this notice.
    A notice of intent must specify the exact name, business address,
and telephone number of the prospective applicant, and must include an
unequivocal statement of intent to submit a development application. A
notice of intent must be served on the applicant(s) named in this
public notice.
    Anyone may submit a protest or a motion to intervene in accordance
with the requirements of Rules of Practice and Procedure, 18 CFR
385.210, 385.211, and 385.214. In determining the appropriate action to
take, the Commission will consider all protests filed, but only those
who file a motion to intervene in accordance with the Commission's
Rules may become a party to the proceeding. Any protests or motions to
intervene must be received on or before the specified deadline date for
the particular application.
    When the application is ready for environmental analysis, the
Commission will issue a public notice requesting comments,
recommendations, terms and conditions, or prescriptions.
    All filings must (1) bear in all capital letters the title
``PROTEST'' or ``MOTION TO INTERVENE,'' ``NOTICE OF INTENT TO FILE
COMPETING APPLICATION,'' or ``COMPETING APPLICATION;'' (2) set forth in
the heading the name of the applicant and the project number of the
application to which the filing responds; (3) furnish the name,
address, and telephone number of the person protesting or intervening;
and (4) otherwise comply with the requirements of 18 CFR 385.2001
through 385.2005. Agencies may obtain copies of the application
directly from the applicant. A copy of any protest or motion to
intervene must be served upon each representative of the applicant
specified in the particular application.

    Dated: November 2, 2012.
 Kimberly D. Bose,
 Secretary.
[FR Doc. 2012-27410 Filed 11-8-12; 8:45 am]
BILLING CODE 6717-01-P


Section 101.120................  Eligibility for            5/22/2013  2/14/2020, [Insert
                                  Equivalent                            Federal Register
                                  Alternative                           citation].
                                  Obligation.
Section 101.121................  Equivalent                 5/22/2013  2/14/2020, [Insert
                                  Alternative                           Federal Register
                                  Obligation.                           citation].
Section 101.122................  Using Supplemental         5/22/2013  2/14/2020, [Insert
                                  Environmental                         Federal Register
                                  Project to Fulfill                    citation].
                                  an Equivalent
                                  Alternative
                                  Obligation.

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------

* * * * *
    (e) * * *

              EPA-Approved Nonregulatory Provisions and Quasi-Regulatory Measures in the Texas SIP
----------------------------------------------------------------------------------------------------------------
                                        Applicable      State approval/
      Name of SIP provision           geographic or        effective     EPA approval date         Comments
                                    nonattainment area       date
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
Houston-Galveston-Brazoria         Houston-Galveston-       12/12/2018  2/14/2020, [Insert
 Redesignation Request and          Brazoria, TX.                        Federal Register
 Maintenance Plan for the 1-hour                                         citation].
 and 1997 8-hour Ozone Standards.
----------------------------------------------------------------------------------------------------------------

* * * * *

0
3. Section 52.2275 is amended by revising paragraphs (j) and (n) to
read as follows:

Sec.  52.2275   Control strategy and regulations: Ozone.

* * * * *
    (j) Determination of Attainment. Effective November 19, 2015, the
EPA has determined that the Houston-Galveston-Brazoria 1-hour ozone
nonattainment area has attained the 1-hour ozone standard.
* * * * *
    (n) Termination of Anti-backsliding Obligations for the Revoked 1-
hour and 1997 8-hour ozone standards. Effective March 16, 2020 EPA has
determined that the Houston-Galveston-Brazoria area has met the Clean
Air Act criteria for redesignation. Anti-backsliding obligations for
the revoked 1-hour and 1997 8-hour ozone standards are terminated in
the Houston-Galveston-Brazoria area.

PART 81--DESIGNATION OF AREAS FOR AIR QUALITY PLANNING PURPOSES

0
4. The authority citation for part 81 continues to read as follows:

    Authority:  42 U.S.C. 7401 et seq.

0
5. Section 81.344 is amended:
0
a. In the table titled ``Texas--Ozone (1-Hour Standard)'' by:
0
i. Removing the footnote number ``2'' in the title heading ``Texas-
Ozone (1-Hour Standard)'' and adding in its place footnote number
``1'';
0
ii. Under column headings ``Designation'' and ``Classification'' in the
both headings for ``Date,'' removing the footnote number ``1'' and
adding in its place the footnote number ``2'';
0
iii. Revising the entry for ``Houston-Galveston-Brazoria Area, TX'';
and
0
iv. Revising footnotes 1, 2, and 4.
0
b. Amend table titled ``Texas--1997 8-Hour Ozone NAAQS [Primary and
Secondary]'' by:
0
i. Adding footnote ``1'' to the table heading;
0
ii. Revising footnotes 1 and 4; and
0
iii. Revising the entry for ``Houston-Galveston-Brazoria Area, TX,''
including the removal of footnote 7.
    The revisions and additions read as follows:

Sec.  81.344   Texas.

* * * * *

                                                  Texas--Ozone
                                              [1-Hour standard] \1\
----------------------------------------------------------------------------------------------------------------
                                                Designation                           Classification
         Designated area         -------------------------------------------------------------------------------
                                       Date \2\              Type              Date \2\              Type
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
Houston-Galveston-Brazoria Area,  See footnote 4....  See footnote 4....  See footnote 4....  See footnote 4.
 TX:.
    Brazoria County \4\
    Chambers County \4\
    Fort Bend County \4\
    Galveston County \4\
    Harris County \4\
    Liberty County \4\
    Montgomery County \4\
    Waller County \4\

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
\1\ The 1-hour ozone standard, designations and classifications are revoked effective June 15, 2005 for areas in
  Texas except the San Antonio area where they are revoked effective April 15, 2009.
\2\ The date at the time designations were revoked is October 18, 2000, unless otherwise noted.
 * * * * * * *
\4\ The Houston-Galveston-Brazoria Area was designated and classified as ``Severe-17'' nonattainment on November
  15, 1990 and was so designated and classified when the 1-hour ozone standard, designations and classifications
  were revoked. The area has since attained the 1-hour ozone standard and met all the Clean Air Act criteria for
  redesignation. All 1-hour ozone standard anti-backsliding obligations for the area are terminated effective
  March 16, 2020.

* * * * *

                                         Texas--1997 8-Hour Ozone NAAQS
                                           [Primary and secondary] \1\
----------------------------------------------------------------------------------------------------------------
                                              Designation \a\                     Category/classification
         Designated area         -------------------------------------------------------------------------------
                                       Date \1\              Type              Date \1\              Type
----------------------------------------------------------------------------------------------------------------

                                                  * * * * * * *
Houston-Galveston-Brazoria, TX:.  See footnote 4....  See footnote 4....  See footnote 4....  See footnote 4.
    Brazoria County \4\
    Chambers County \4\
    Fort Bend County \4\
    Galveston County \4\
    Harris County \4\
    Liberty County \4\
    Montgomery County \4\
    Waller County \4\

                                                  * * * * * * *
----------------------------------------------------------------------------------------------------------------
 * * * * * * *
\1\ The 1997 8-hour ozone NAAQS, designations and classifications were revoked effective April 6, 2015. The date
  at the time designations were revoked is June 15, 2004, unless otherwise noted.
 * * * * * * *
\4\ The Houston-Galveston-Brazoria, TX area was designated nonattainment effective June 15, 2004 and was
  classified as ``Severe-15'' effective October 31, 2008. The area has since attained the 1997 8-hour ozone
  standard and met all the Clean Air Act criteria for redesignation. All 1997 8-hour ozone standard anti-
  backsliding obligations for the area are terminated effective March 16, 2020.

* * * * *
[FR Doc. 2020-02053 Filed 2-13-20; 8:45 am]
 BILLING CODE 6560-50-P